• Publications
  • Influence
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
Thomas J. Walsh, Elias J. Anaissie, David W. Denning, Raoul Herbrecht, Dimitrios P. Kontoyiannis, Kieren A. Marr, Vicki A. Morrison, Brahm H Segal, William J. Steinbach, David A. Stevens, Jo-Anne vanExpand
  • 2,320
  • 128
  • PDF
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.
During the past several decades, there has been a steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients. However, there is substantialExpand
  • 2,271
  • 110
  • PDF
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients orExpand
  • 957
  • 52
  • PDF
Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.
Because of the difficulties of recognizing allergic bronchopulmonary aspergillosis (ABPA) in the context of cystic fibrosis (because of overlapping clinical, radiographic, microbiologic, andExpand
  • 549
  • 36
  • PDF
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.
In a screen of drugs previously tested in humans we identified itraconazole, a systemic antifungal, as a potent antagonist of the Hedgehog (Hh) signaling pathway that acts by a mechanism distinctExpand
  • 368
  • 27
  • PDF
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.
No controlled trials of therapy for invasive aspergillosis have been done. This review appraises 2,121 cases reported in 497 articles in the literature and analyzes 440 courses of treatment ofExpand
  • 896
  • 25
Molecular and Phenotypic Characterization of Genotypic Candida albicans Subgroups and Comparison withCandida dubliniensis and Candida stellatoidea
ABSTRACT There have been increased reports of the isolation of unusual genotypic groups of Candida albicans (groups C and D) based on a well-defined genotypic method; this method uses cellular DNAExpand
  • 193
  • 23
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
BACKGROUND Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Current treatments provide limited benefit. Posaconazole is an extended-spectrumExpand
  • 660
  • 22
  • PDF
Practice Guidelines for Diseases Caused by Aspergillus
Aspergillosis comprises a variety of manifestations of infection. These guidelines are directed to 3 principal entities: invasive aspergillosis, involving several organ systems (particularlyExpand
  • 737
  • 21
  • PDF
Itraconazole resistance in Aspergillus fumigatus.
Invasive aspergillosis is an increasingly frequent opportunistic infection in immunocompromised patients. Only two agents, amphotericin B and itraconazole, are licensed for therapy. Itraconazole actsExpand
  • 446
  • 19
  • PDF